ライフサイエンスコーパス: palpitation

1 e to toxicity (deep venous thrombosis, chest palpitations).

2 ade 1 sinus bradycardia; and one had grade 1 palpitation.

3 ted with progressively worsening dyspnea and palpitations.

4 effects include pallor, tremor, anxiety, and palpitations.

5 mic, or gastrointestinal symptoms, and heart palpitations.

6 mic, or gastrointestinal symptoms, and heart palpitations.

7 s-loop event recording for the evaluation of palpitations.

8 ction presented with shortness of breath and palpitations.

9 le with AF, such as fatigue, dyspnea, and/or palpitations.

10 ant sensations such as tachycardia and heart palpitations.

11 bited systemic symptoms, primarily fever and palpitations.

12 h minimal activity or positional change, and palpitations.

13 First presentation symptoms included palpitations (33%), syncope (27%), sustained VT (27%), a

14 chest pain (37.4% versus 23.6%; P=0.010) and palpitations (39.3% versus 26.1%; P=0.016) than male pat

15 c for 24 months (Q1-Q3, 16-60); 73% reported palpitations, 47% fatigue, and 30% (near-)syncope.

16 therapy for overall symptoms (-41%, P<0.01), palpitations (-58%, P=0.0001), and dyspnea (-37%, P<0.05

17 overall symptoms (-48% versus -4%, P<0.005), palpitation (-62% versus -5%, P<0.001), dyspnea (-44% ve

18 The most common symptom was palpitation (85.7%) followed by shortness of breath (25%

19 Most common symptoms include palpitations (86%), chest discomfort (47%), and dyspnea

20 Except for palpitation after 7 min, the only subjective symptom was

21 milar to adrenaline, to induce sensations of palpitation and dyspnea in healthy individuals (n=23) du

22 lified by the poor correlation found between palpitations and cardiac arrhythmias.

23 History A 47-year-old man presented with palpitations and decreased exercise tolerance.

24 Palpitations and dyspnea are fundamental to the human ex

25 y sensation, with all participants reporting palpitations and dyspnea at the 2 mug dose.

26 B.G. and A.M.) to examine whether triggering palpitations and dyspnea via stimulation of non-chemosen

27 beta-Adrenergic stimulation elicits heart palpitations and dyspnea, key features of acute anxiety

28 with complaints of intermittent chest pain, palpitations and exertional dyspnoea.

29 re prevalent in women and have symptoms (eg, palpitations and fatigue) that may be confounded with CA

30 ifth decades of life either with symptoms of palpitations and syncope associated with ventricular tac

31 ressors and a family history of intermittent palpitations and syncope in his brother raised suspicion

32 cardiac diseases, alongside symptoms such as palpitations and syncope.

33 nce; 84 had chest pain with activity; 75 had palpitations and/or tachycardia.

34 expensive and can cause vomiting, headache, palpitation, and occasionally seizures.

35 in New York Heart Association class 2, 5 had palpitations, and 2 had a history of syncope.

36 Exertional dyspnea, chest pain, palpitations, and ankle swelling were reported by 47 (43

37 ss on standing, which may worsen to syncope, palpitations, and blue-purple ankle discoloration, and i

38 omach pain, fainting, loose stools/diarrhea, palpitations, and sleep problems), even after adjustment

39 extremely anxious with heart rate increases, palpitations, and symptoms of psychological arousal.

40 pical symptoms include dyspnoea, chest pain, palpitations, and syncope.

41 luding anxiety, insomnia, tremulousness, and palpitations, as well as bone loss and possibly increase

42 or establishing a diagnosis in patients with palpitations but are less effective for establishing a d

43 orders are widely used for the evaluation of palpitations, but the optimal duration of monitoring is

44 onal malaise, fatigue, brain fog, dizziness, palpitations, change in smell or taste, thirst, chronic

45 n fog, dizziness, gastrointestinal symptoms, palpitations, changes in sexual desire or capacity, loss

46 e effects (such as tachycardia; bradycardia; palpitation; changing PR, QRS, QTc intervals in electroc

47 , they may cause important symptoms, such as palpitations, chest discomfort, breathlessness, anxiety,

48 supplement-related adverse events involving palpitations, chest pain, or tachycardia, and 58.0% (95%

49 iac arrest, thromboembolism, chest pain, and palpitations, compared to uninfected controls.

50 sturbance, and tension, and symptoms such as palpitations, dry mouth, and sweating.

51 o recurrent systemic symptoms (eg, flushing, palpitations, dyspepsia, diarrhea, bone pain) that can b

52 significant improvement in several symptoms (palpitations, dyspnea).

53 Symptoms of AF include palpitations, dyspnea, chest pain, presyncope, exertiona

54 commonly asymptomatic but can also result in palpitations, dyspnea, presyncope, and fatigue.

55 Type of symptoms (palpitations, fatigue, and [near-]syncope), PVC burden o

56 Palpitations following drug administration were reported

57 festations, including epigastric sensations, palpitations, goosebumps and syncope (fainting).

58 Although the most common symptom is palpitations, it can be accompanied by a myriad of sympt

59 symptoms including chest pain, dyspnoea, and palpitations, it often mimics more common disorders such

60 Persistent symptoms (eg, heart palpitations, lightheadedness, fatigue) despite resoluti

61 ts had higher incidence of dyspnea, fatigue, palpitations, loss of taste/smell, and neurocognitive sy

62 te of patient-reported symptoms (chest pain, palpitations, migraines, dyspnea, and rash).

63 Pre-operative symptoms included palpitations (n = 69), edema (n = 30), and previous stro

64 ression model, the combination of migraines, palpitation, nausea, tiredness, and sleep disorders expl

65 rdiac channelopathy that can be mistaken for palpitations, neurocardiogenic syncope, and epilepsy.

66 nths), new MacroATs, atrial fibrillation, or palpitations occurred in 3 of 16 patients.

67 o record 20 or 30 seconds twice daily and if palpitations occurred.

68 emonstrable cardiac arrhythmias than are the palpitations of other patients.

69 of resting heartbeat, we have found that the palpitations of patients who somatize more and have more

70 Dropouts occurred due to palpitations (one patient on eliglustat), myocardial inf

71 breathlessness (OR 3.43, 95% CI 3.29-3.58), palpitations (OR 2.51, OR 2.36-2.66), chest pain (OR 2.0

72 were age at study > or =18 years (OR, 3.3), palpitations (OR, 2.8), prior palliative surgery (OR, 3.

73 ht sweats, hemoptysis, wheezing, chest pain, palpitations, orthopnea, paroxysmal nocturnal dyspnea, s

74 atus was associated with higher frequency of palpitation (P=0.004), implantable cardioverter defibril

75 Palpitations, presyncope/syncope, stroke symptoms and ch

76 repair of the mitral valve, the dyspnea and palpitations resolved.

77 e associated with physical symptoms, such as palpitations, shortness of breath, and dizziness.

78 The most common presenting symptoms were palpitations, syncope, and sudden cardiac death (SCD) in

79 d with an increased risk of tachyarrhythmia, palpitations, syncope, and sudden death.

80 ent adverse effect (17 reports), followed by palpitations, tachycardia, or both (13); stroke (10); an

81 s had a greater prevalence of chest pain and palpitations than male patients, but lesser cardiac invo

82 ing the vehicle, 22 percent had dizziness or palpitations that did not necessitate stopping the vehic

83 yncopal episode, 11 percent had dizziness or palpitations that necessitated stopping the vehicle, 22

84 termittent chest pain and a 5-day history of palpitations that were not associated with exercise.

85 In patients referred for evaluation of palpitations, the diagnostic yield of continuous-loop ev

86 everal consequences, ranging from uneventful palpitations to lethal ventricular arrhythmias, in the p

87 verse effects, such as increased heart rate, palpitations, transient decrease in PaO2, and tremor.

88 of thyrotoxicosis include anxiety, insomnia, palpitations, unintentional weight loss, diarrhea, and h

89 ically, new-onset or worsening migraines and palpitations were more frequent in nickel-hypersensitive

90 ess, hot flush, headache, hyperhidrosis, and palpitations were reported most frequently.

91 odes of shortness of breath, chest pain, and palpitations with exertion, but more recently he had bee

92 Innocent murmur and syncope or palpitations with no other indications of cardiovascular